For Immediate Release
Chicago, IL – March 15, 2013 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include America Movil S.A.B. (AMX), Grupo Televisa S.A.B (TV), Telefonica S.A. (TEF), NII Holdings Inc. (NIHD) and Genomic Health (GHDX).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Thursday’s Analyst Blog:
Mexico to Reform Telecom Sector
A new bill proposed by Mexican President Enrique Pena Nieto early this week highlights several measures to reform its telecom and television industry. The main objective of introducing this bill is to bring greater uniformity and transparency in the sector and to curb the concentration of power lying with predominant players who dictate market behavior.
A major highlight of this bill is to introduce a new regulatory body -- Federal Telecommunications Institute -- that replaces the existing body -- Cofetel (Comisión Federal de Telecomunicaciones). The bill also proposes to remove the antitrust agency -- the Federal Competition Commission -- by allocating its responsibilities to the Federal Telecommunications Institute.
Through these amendments, the government expects strong participation in controlling industry activities. The bill demonstrates several key points that the Mexican government intends to undertake. One of these include barring operators from pushing regulatory rulings through injunctions during court appeals. Further, the bill imposes stringent action for unfair trade practice through stiffer penalties and may require fragmenting a company to promote fair competition.
However, the proposal has struck a discordant note on the Mexican telecom and television industry as it unfavorably targets giant corporations -- America Movil S.A.B. (AMX) and Grupo Televisa S.A.B (TV). The proposal stresses on implementation of the asymmetric regulations that faced severe condemnation by America Movil.
The rule implies that predominant players who control majority of the market share as in the case of America Movil will have to pay higher mobile termination rates (MTRs) to smaller peers while receive less from them for network interconnection. Through Telcel and Telmex, America Movil commands about 70% market share, while the Spanish wireless operator Telefonica S.A. (TEF) controls nearly 22% of the Mexican market share.
The rule has also cast the cable company Televisa under examination as it controls over 73% of the market share in the television business, according to market reports. The proposal includes the creation of two new digital broadcast networks that would compete with Televisa and TV Azteca.
In addition, it highlights creation of a non-profit television company that would provide cable services across the country. Further, these companies would be prohibited from participating in any government-related spectrum auction in the future to expand national television networks.
This is not the first time that the company has been hit by regulatory interventions. Earlier, in 2010, Televisa abandoned its wireless venture with Nextel de Mexico, a subsidiary of NII Holdings Inc. (NIHD) due to prolonged legal battles.
Given the nature of the Mexican telecom and television market characterized by extreme level of competition and quasi-monopolistic practices, the proposed reform comes as no surprise. The bill, if approved, would mark a pivotal role in shaping the telecom industry in Mexico and decide the prospects for these carriers in Mexico who have so far reaped large profits and grown as market leaders throughout Latin America.
Genomic Health Reveals Positive Results
Recently, Genomic Health (GHDX) announced the positive result of a study on Oncotype DX to estimate the risk of loco-regional recurrence (:LRR) in node-positive, estrogen receptor breast cancer patients, who were treated with adjuvant hormonal therapy and chemotherapy. The study was first presented in the 2013 Society of Surgical Oncology, Md.
Genomic Health encouragingly noted that Oncotype DX remains significantly effective for the ER-positive lymph node-positive breast cancer patients. According to the data, apart from identifying patents who will respond positively to adjuvant chemo-endocrine therapy, Oncotype DX can help the physicians’ decision on radiation treatment.
The company's lead product, the Oncotype DX breast cancer, has already been proved effective in predicting chemotherapy benefit in both node-negative and node-positive breast cancer. It is used to predict the likelihood of cancer recurrence in ductal carcinoma in situ (:DCIS), patient survival within 10 years of diagnosis and chemotherapy benefit for early stage breast cancer patients.
The latest result will further enhance this product’s efficacy by finding the intensity and extent of radiation in breast cancer patients with node-positive disease.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: https://twitter.com/zacksresearch
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339
More From Zacks.com